1. Scrip
  2. >>R&D
  3. >>Clinical Trials

Structure Therapeutics Aims For Best-In-Class Oral Incretin

 
• By Elizabeth Cairns

Phase II data are positive but early, and drawing any big conclusions might be premature.    

Weight-loss-pills-tape-measure_3113223_1200x675

What a difference six months makes. In the depths of last winter the market value of Structure Therapeutics, Inc. almost halved when mid-stage data on its lead asset, the oral GLP-1 agonist GSBR-1290, disappointed in a trial in patients with type 2 diabetes. (Also see "Structure’s Oral Weight Loss Drug Data Underperforms A Big Rival" - Scrip, 18 December, 2023.)

Key Takeaways
  • Structure Therapeutics’ oral GLP-1 agonist, GSBR-1290, showed greater weight loss than rival pills in a mid-stage trial.
  • But the data are at an early time point, and further trials will be necessary to back them up

Yesterday, the group disclosed strong data with the same molecule from a different trial in obese patients, and its share price has climbed to $52.74 on the NASDAQ – just shy of where it was before the December fall

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Clinical Trials

Azafaros Banks Over €130m To Advance Nizubaglustat Into Phase III

 
• By Kevin Grogan

The therapy has been developed for GM1 and GM2 gangliosidoses and Niemann-Pick disease type C.

Lilly Builds Obesity Momentum With New SURMOUNT Data Besting Novo Nordisk

 
• By Alaric DeArment

The presentation and publication of the Phase IIIb study showing greater efficacy for Zepbound over Wegovy come at a time when competition has been heating up between the two obesity medications.

Insilico Fast-Tracks First AI-Designed TNIK Inhibitor For IPF

 
• By Dexter Jie Yan

InSilico will leapfrog Phase IIb to progress its AI-generated candidate for idiopathic pulmonary fibrosis directly into a Phase III trial in China, as it prepares for an IPO in Hong Kong.

Pipeline Watch: Six Approvals And Thirteen Phase III Readouts

Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events and approvals announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.

More from R&D

Which Firms Are Most Exposed To Prasad’s Possible Accelerated Approvals Clampdown?

 
• By Andrew McConaghie

Vaccine and accelerated approvals are expected to face greater scrutiny under new CBER leader Vinay Prasad, but he has promised “no light switch change” to policy, giving some reassurance to companies whose share prices have been battered.

Pipeline Watch: Six Approvals And Thirteen Phase III Readouts

Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events and approvals announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.

Viatris Will File ‘Fast-Acting’ Meloxicam For FDA Approval This Year

 
• By Joseph Haas

Seven years after acquiring it, Viatris will seek approval of a meloxicam formulation for acute pain backed by data from two Phase III studies in post-surgical pain settings.